BCL11A and Schnyder corneal dystrophy: Approved platforms like betibeglogene autotemcel (for β-thalassemia) and investigational therapies like exa-cel (for both SCD and β-thalassemia) rely on either addition of a functional β-globin gene or reactivation of endogenous γ-globin via BCL11A disruption.